BioStem Technologies, Inc.
BSEM
$3.85
-$0.11-2.68%
OTC PK
| 03/31/2026 | 09/30/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -61.57% | -43.12% | -242.83% | -242.83% | -61.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.57% | -43.12% | -242.83% | -242.83% | -61.90% |
| Cost of Revenue | 178.42% | -71.58% | -81.72% | -81.72% | -61.64% |
| Gross Profit | -75.13% | -34.61% | -171.48% | -171.48% | -61.91% |
| SG&A Expenses | 35.05% | 33.76% | -86.21% | -86.21% | -76.77% |
| Depreciation & Amortization | 900.74% | 6.67% | 14.74% | 14.74% | 4.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.14% | -1.06% | -106.65% | -106.65% | -71.26% |
| Operating Income | -269.25% | -84.41% | -98.72% | -98.72% | 13.91% |
| Income Before Tax | -267.02% | -83.95% | -97.93% | -97.93% | 18.86% |
| Income Tax Expenses | -- | -69.66% | -67.92% | -67.92% | 15.84% |
| Earnings from Continuing Operations | -325.68% | -88.84% | -108.98% | -108.98% | 19.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -325.68% | -88.84% | -108.98% | -108.98% | 19.96% |
| EBIT | -269.25% | -84.41% | -98.72% | -98.72% | 13.91% |
| EBITDA | -257.34% | -83.88% | -98.05% | -98.05% | 13.80% |
| EPS Basic | -323.29% | -89.13% | -108.76% | -108.76% | 17.38% |
| Normalized Basic EPS | -265.29% | -84.36% | -97.97% | -97.97% | 16.27% |
| EPS Diluted | -448.93% | -90.63% | -111.61% | -111.61% | -11.76% |
| Normalized Diluted EPS | -360.22% | -85.41% | -97.28% | -97.28% | -12.53% |
| Average Basic Shares Outstanding | 1.06% | 2.60% | 2.53% | 2.53% | 2.19% |
| Average Diluted Shares Outstanding | -35.82% | 9.97% | -23.56% | -23.56% | 35.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |